AAAAAA
Results: 1-25/40
Authors:
AAPRO M
PICCART M
Citation: M. Aapro et M. Piccart, BREAST-CANCER, Critical reviews in oncology/hematology, 27(2), 1998, pp. 135-137
Authors:
KLIJN J
HAMILTON A
BEEX L
MAURIAC L
PARIDAENS R
ROY JA
AWADA A
VANVRECKEM A
PALMER P
PICCART M
Citation: J. Klijn et al., EORTC-10941 - FINAL RESULTS OF A PHASE-II STUDY OF LIAROZOLE FUMARATEIN PATIENTS WITH METASTATIC BREAST-CANCER, European journal of cancer, 34, 1998, pp. 72-72
Authors:
DEVALERIOLA D
AWADA A
VANVRECKEM A
HABBOUBI N
RIVA A
PICCART M
Citation: D. Devaleriola et al., INFLUENCE OF AMIFOSTINE (A) ON THE TOXICITY AND PHARMACOKINETICS (PK)OF DOCETAXEL (D) IN BREAST-CANCER PATIENTS - AN EORTC-IDBBC STUDY, European journal of cancer, 34, 1998, pp. 76-76
Authors:
HAMILTON A
COLEMAN R
MAURIAC L
AWADA A
PICCART M
VANVRECKEM A
BRUNING P
Citation: A. Hamilton et al., EORTC-10968 - PHASE-I STUDY OF CAELYX(TM) AT A 6-WEEK INTERVAL IN PATIENTS WITH METASTATIC BREAST-CANCER, European journal of cancer, 34, 1998, pp. 77-77
Authors:
BONNEFOI H
DIEBOLDBERGER S
HAMILTON A
VANDEVIJVER M
MACGROGAN G
SHEPHERD L
AMARAL N
RAOUST I
DRIJKONINGEN M
THERASSE P
PICCART M
Citation: H. Bonnefoi et al., A STUDY OF MOLECULAR MARKERS WITH POTENTIAL PROGNOSTIC AND PREDICTIVEVALUE (C-ERBB-2, P53, CYCLIN D1, MIB1, ER AND PGR) IN LOCALLY ADVANCED BREAST-CANCER TREATED WITH NEOADJUVANT DOSE-INTENSIVE CHEMOTHERAPY IN AN EORTC-NCIC-SAKK RANDOMIZED PHASE-III STUDY, European journal of cancer, 34, 1998, pp. 133-133
Authors:
PICCART M
Citation: M. Piccart, MORE ON DOSE-INTENSITY OF ANTHRACYCLINES IN BREAST-CANCER - RESPONSE, Annals of oncology, 9(4), 1998, pp. 461-461
Authors:
THERASSE P
MAURIAC L
WELNICKA M
BRUNING P
CUFER T
TOMIAK E
CURRAN D
RAMIREZ A
KOOPMANSCHAP M
PICCART M
Citation: P. Therasse et al., AN EORTC-NCIC-SAKK NEOADJUVANT RANDOMIZED PHASE-III STUDY COMPARING CEF (5FU, EPIRUBICIN, CYCLOPHOSPHAMIDE) VS DOSE INTENSIFIED EC-CSF (FILGRASTIM) IN LOCALLY ADVANCED BREAST-CANCER (LABC) - UPDATED RESULTS INCLUDING QUALITY-OF-LIFE(G), Annals of oncology, 9, 1998, pp. 63-63
Authors:
KLIJN JGM
BEEX L
MAURIAC L
VANZIJL J
VEYRET C
WILDIERS J
JASSEM J
BURGHOUTS J
PICCART M
MIGNOLET F
DUCHATEAU L
Citation: Jgm. Klijn et al., COMBINED TREATMENT WITH THE LHRH-AGONIST BUSERELIN (LHRH-A) AND TAMOXIFEN (TAM) VS SINGLE TREATMENT WITH EACH DRUG ALONE IN PREMENOPAUSAL METASTATIC BREAST-CANCER - FINAL RESULTS OF EORTC-STUDY-10881, Annals of oncology, 9, 1998, pp. 540-540
Authors:
AWADA A
DEVALERIOLA D
GIL T
KERGER J
SELLESLAGS J
MARIEN K
VANVRECKEM A
BRASSINNE C
HENNEBERT P
DEWJI R
RIVA A
PICCART M
Citation: A. Awada et al., INFLUENCE OF THE CYTOPROTECTIVE AGENT AMIFOSTINE ON TOXICITY AND PHARMACOKINETICS (PK) OF DOCETAXEL (D) IN METASTATIC BREAST-CANCER (MBC) -A FEASIBILITY STUDY OF THE EORTC-INVESTIGATIONAL DRUG BRANCH FOR BREAST-CANCER (IDBBC), Annals of oncology, 9, 1998, pp. 208-208
Authors:
KERGER J
DEVALERIOLA D
BLEIBERG H
BARTHOLOMEUS S
BRASSINNE C
WYTHOUCK H
SOULAS F
CAZENAVE I
PICCART M
Citation: J. Kerger et al., CLINICAL AND PHARMACOKINETIC PHASE-I STUDY OF THE COMBINATION OF DOCETAXEL (TXT), CISPLATIN (DDP) AND FLUOROURACIL (5-FU) IN PATIENTS WITH SOLID TUMORS, Annals of oncology, 9, 1998, pp. 364-364
Authors:
THEUNISSEN K
BIGANZOLI L
MAERTENS J
ZACHEE P
PARIDAENS R
VANOOSTEROM A
BRON D
PICCART M
BOOGAERTS M
Citation: K. Theunissen et al., PERIPHERAL-BLOOD PROGENITOR-CELL COLLECTION AFTER DOCETAXEL AND LENOGRASTIM IN PATIENTS WITH METASTATIC BREAST-CANCER, British Journal of Haematology, 102(1), 1998, pp. 74-74
Authors:
ADRIAENSSEN I
PICCART M
ROY JA
BOES GH
Citation: I. Adriaenssen et al., RESOURCE IMPLICATIONS OF PACLITAXEL CISPLATINUM VERSUS CYCLOPHOSPHAMIDE/CISPLATINUM IN THE TREATMENT OF ADVANCED OVARIAN-CANCER/, European journal of cancer, 33, 1997, pp. 1-1
Authors:
PARIDAENS R
BRUNING P
KLIJN J
GAMUCCI T
BIGANZOLI L
VANVRECKEM A
BOES GH
CURRAN D
PICCART M
Citation: R. Paridaens et al., TAXOL (T) VERSUS DOXORUBICIN (D) AS FIRST-LINE CHEMOTHERAPY (CT) IN ADVANCED BREAST-CANCER (ABC) - AN EORTC RANDOMIZED STUDY WITH CROSSOVER, European journal of cancer, 33, 1997, pp. 645-645
Authors:
WANDERS J
HUININK WWT
PAVLIDIS N
KAYE SB
SESSA C
LEHNERT M
PICCART M
PARIDAENS R
WISSEL P
HANAUSKE AR
Citation: J. Wanders et al., PHASE-II STUDIES WITH GI147211 (GI) IN BREAST (B), COLORECTAL (C) ANDNON-SMALL-CELL LUNG-CANCER (N), European journal of cancer, 33, 1997, pp. 705-705
Authors:
AWADA A
DEVALERIOLA D
CORNEZ N
KERGER J
VANVRECKEM A
BARTHOLOMEUS S
SELLESLAGS J
DEWJI R
PICCART M
Citation: A. Awada et al., DOCETAXEL (D) IN COMBINATION WITH AMIFOSTINE (A) IN METASTATIC BREAST-CANCER (MBC) - A FEASIBILITY AND PHARMACOKINETIC STUDY OF THE EORTC-INVESTIGATIONAL DRUG BRANCH FOR BREAST-CANCER (IDBBC), European journal of cancer, 33, 1997, pp. 710-710
Authors:
THODTMANN R
AWADA A
PICCART M
HOPPENER F
WANDERS J
VONBROEN IM
HANAUSKE AR
Citation: R. Thodtmann et al., CLINICAL AND PHARMACOKINETIC EVALUATION OF THE NEW BISNAPHTALAMIDE LU-79553 ADMINISTERED EVERY 21 DAYS IN PATIENTS WITH SOLID TUMORS - AN EORTC ECSG STUDY/, European journal of cancer, 33, 1997, pp. 1106-1106
Authors:
KAYE SB
PICCART M
AAPRO M
FRANCIS P
KAVANAGH J
Citation: Sb. Kaye et al., PHASE-II TRIALS OF DOCETAXEL (TAXOTERE(R)) IN ADVANCED OVARIAN-CANCER- AN UPDATED OVERVIEW, European journal of cancer, 33(13), 1997, pp. 2167-2170
Authors:
RUSTHOVEN JJ
DEVRIES EGE
DALE DC
PICCART M
GLASPY J
HAMILTON A
Citation: Jj. Rusthoven et al., CONSENSUS ON THE USE OF NEUTROPHIL-STIMULATING HEMATOPOIETIC GROWTH-FACTORS IN CLINICAL-PRACTICE - AN INTERNATIONAL VIEWPOINT, International journal of antimicrobial agents, 8(4), 1997, pp. 263-275
Authors:
PICCART M
Citation: M. Piccart, NEW CYTOTOXIC AGENTS, Cancer treatment reviews, 23, 1997, pp. 59-64
Authors:
DEVALERIOLA D
AWADA A
ROY JA
DILEO A
BIGANZOLI L
PICCART M
Citation: D. Devaleriola et al., BREAST-CANCER THERAPIES IN DEVELOPMENT - A REVIEW OF THEIR PHARMACOLOGY AND CLINICAL POTENTIAL, Drugs, 54(3), 1997, pp. 385-413
Authors:
TOMIAK E
PICCART M
MIGNOLET F
SAHMOUD T
PARIDAENS R
NOOY M
BEEX L
FENTIMAN IS
MULLER A
VANDERSCHUEREN E
RUBENS RD
Citation: E. Tomiak et al., CHARACTERIZATION OF COMPLETE RESPONDERS TO COMBINATION CHEMOTHERAPY FOR ADVANCED BREAST-CANCER - A RETROSPECTIVE EORTC BREAST GROUP-STUDY, European journal of cancer, 32A(11), 1996, pp. 1876-1887
Authors:
PICCART M
Citation: M. Piccart, TREATMENT OF ADVANCED BREAST-CANCER - CURRENT STATUS, Anti-cancer drugs, 7, 1996, pp. 5-7
Authors:
BODY JJ
COLEMAN RE
PICCART M
Citation: Jj. Body et al., USE OF BISPHOSPHONATES IN CANCER-PATIENTS, Cancer treatment reviews, 22(4), 1996, pp. 265-287
Authors:
TRIVEDI S
PICCART M
MUQUARDT C
GILOT N
HADIY S
PATEL D
LECLERCQ G
Citation: S. Trivedi et al., TAMOXIFEN AZIRIDINE LABELING OF THE ESTROGEN-RECEPTOR - POTENTIAL UTILITY IN DETECTING BIOLOGICALLY AGGRESSIVE BREAST-TUMORS, Breast cancer research and treatment, 40(3), 1996, pp. 231-241
Authors:
PARIDAENS R
BRUNING P
CALABRESI F
AWADA A
ROY JA
KUSENDA Z
PICCART M
Citation: R. Paridaens et al., TAXOL OR DOXORUBICIN AS FIRST LINE CHEMOTHERAPY IN ADVANCED BREAST-CANCER (ABC) - A PROSPECTIVE RANDOMIZED PHASE-II STUDY WITH CROSSOVER, European journal of cancer, 31A, 1995, pp. 346-346